Loading…
Asston Pharmaceuticals (BSE 544445)₹151.25+7.19%Pharmaceuticals
In the Mar 2026 quarter (standalone), Asston Pharmaceuticals reported sales of ₹10.03 Cr, up 10.8% from Mar 2025, and net profit of ₹0.47 Cr, down 75.8% year on year. For the year to Mar 2026, sales were ₹25.42 Cr and net profit ₹3.86 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 15.92 | 9.05 | 15.39 | 10.03 |
| Expenses | 13.75 | 5.90 | 13.23 | 12.89 |
| Operating Profit | 2.27 | 3.19 | 2.24 | −2.81 |
| OPM % | 14.1% | 35.0% | 14.4% | −27.9% |
| Other Income | 0.63 | −0.06 | −1.85 | 4.62 |
| Interest | 0.43 | 0.54 | 0.29 | 0.37 |
| Depreciation | 0.01 | 0.01 | 0.06 | 0.24 |
| Profit before tax | 2.47 | 2.57 | 0.03 | 1.23 |
| Tax % | 22.8% | 23.4% | −50.0% | 59.9% |
| Exceptional items | 0.00 | 0.00 | −3.34 | 0.00 |
| Net Profit | 1.89 | 1.94 | 0.02 | 0.47 |
| EPS (Rs) | 24.23 | 3.10 | 0.03 | 0.55 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales | 9.57 | 6.53 | 15.99 | 24.98 | 25.42 |
| Expenses | 9.99 | 5.03 | 12.25 | 19.65 | 26.12 |
| Operating Profit | −0.37 | 1.53 | 3.83 | 5.45 | −0.58 |
| OPM % | −3.8% | 23.2% | 23.8% | 21.7% | −2.3% |
| Other Income | 0.95 | 0.64 | 0.24 | 0.56 | 6.10 |
| Interest | 0.44 | 0.73 | 0.77 | 0.96 | 0.64 |
| Depreciation | 0.00 | 0.03 | 0.05 | 0.03 | 0.31 |
| Profit before tax | 0.17 | 1.42 | 3.26 | 5.03 | 4.61 |
| Tax % | 31.3% | 25.6% | 25.2% | 23.1% | 15.9% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 |
| Net Profit | 0.10 | 1.05 | 2.42 | 3.84 | 3.86 |
| EPS (Rs) | 1.56 | 15.13 | 30.99 | 6.13 | 4.54 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0.69 | 0.69 | 0.77 | 6.25 | 8.49 |
| Reserves | 0.22 | 1.28 | 6.38 | 4.74 | 30.26 |
| Borrowings | 3.32 | 5.25 | 6.82 | 7.26 | 5.12 |
| Other Liabilities | 5.23 | 6.44 | 6.67 | 9.80 | 7.67 |
| Total Liabilities | 9.46 | 13.66 | 20.64 | 28.05 | 51.54 |
| Fixed Assets | 0.91 | 1.12 | 0.96 | 0.95 | 10.66 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 8.55 | 12.54 | 19.68 | 27.10 | 40.88 |
| Inventories | 0.51 | 1.51 | 1.45 | 0.73 | 0.78 |
| Trade receivables | 6.41 | 8.62 | 16.74 | 24.60 | 36.60 |
| Cash & equivalents | 0.15 | 0.13 | 0.02 | 0.21 | 1.30 |
| Total Assets | 9.46 | 13.66 | 20.64 | 28.05 | 51.54 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from operating activity | −1.20 | −0.33 | −3.98 | −0.04 | −10.19 |
| Cash from investing activity | 0.00 | −0.92 | −0.02 | 0.74 | −9.95 |
| Cash from financing activity | 1.30 | 1.22 | 3.87 | −0.52 | 21.24 |
| Net cash flow | 0.09 | 0.00 | −0.11 | 0.18 | 1.08 |
| Capex | 0.00 | 0.24 | 0.00 | 0.02 | 10.05 |
| Free cash flow | −1.20 | −0.58 | −3.99 | −0.07 | −20.29 |
| CFO / OP % | 322.0% | −20.1% | −92.1% | 0.0% | 1,368.0% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor days | 243 | 481 | 381 | 358 | 524 |
| Inventory days | 28 | 205 | 55 | 20 | 17 |
| Days payable | 247 | 755 | 218 | 154 | 121 |
| Cash conversion cycle | 23 | −71 | 216 | 221 | 418 |
| Working capital days | −12 | 44 | 163 | 179 | 434 |
| ROCE % | — | 37.1% | 37.7% | 36.6% | 16.8% |
For the Mar 2026 quarter, Asston Pharmaceuticals reported sales of ₹10.03 Cr, up 10.8% year on year and net profit of ₹0.47 Cr, down 75.8% year on year. The operating margin was −27.9%.
Asston Pharmaceuticals' sales for the year to Mar 2026 were ₹25.42 Cr.
Net profit for the year to Mar 2026 was ₹3.86 Cr. Earnings per share over the same trailing period were ₹4.54.
Asston Pharmaceuticals reported borrowings of ₹5.12 Cr at Mar 2026, against cash and equivalents of ₹1.30 Cr.
Cash from operations was −₹10.19 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹20.29 Cr.